Glutarimide

Glutarimide is a heterocyclic compound with a six-membered piperidine ring containing two ketone groups at positions 2 and 6, forming a dicarboximide structure. N-Acyl-glutarimides are key intermediates in N–C(O) cross-coupling reactions due to their destabilized amide bond, enabling applications in organic synthesis. == Pharmacology ==

Glutarimide itself lacks direct pharmacological activity but is a critical scaffold in several drugs. Derivatives like thalidomide and lenalidomide bind to cereblon (CRBN), an E3 ubiquitin ligase adaptor, promoting protein degradation and exerting immunomodulatory and anti-angiogenic effects. Cycloheximide inhibits protein synthesis by blocking translation elongation in eukaryotic cells, making it a valuable research tool. Glutarimide antibiotics, such as 9-methylstreptimidone, exhibit antiviral, antitumor, and antifungal activities through protein biosynthesis inhibition. The glutarimide moiety’s interaction with biological targets underpins its pharmacological versatility. == History ==

Glutarimide was first synthesized in the early 20th century from glutaric acid, initially valued for its synthetic utility. Its pharmacological relevance emerged with thalidomide in the 1950s, marketed as a sedative but withdrawn in 1961 after causing thousands of birth defects. Thalidomide’s reapproval in 1998 for ENL and later for multiple myeloma led to the development of safer IMiDs like lenalidomide. Glutarimide remains a key scaffold in modern drug design, particularly for CRBN-targeted therapies. == See also ==